A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction.

MLA

Zhang, Yuan, et al. “A New Anti-Fibrotic Drug Attenuates Cardiac Remodeling and Systolic Dysfunction Following Experimental Myocardial Infarction.” International Journal of Cardiology, vol. 168, no. 2, Sept. 2013, pp. 1174–85. EBSCOhost, https://doi.org/10.1016/j.ijcard.2012.11.067.

APA

Zhang, Y., Elsik, M., Edgley, A. J., Cox, A. J., Kompa, A. R., Wang, B., Tan, C. Y. R., Khong, F. L., Stapleton, D. I., Zammit, S., Williams, S. J., Gilbert, R. E., Krum, H., & Kelly, D. J. (2013). A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction. International Journal of Cardiology, 168(2), 1174–1185. https://doi.org/10.1016/j.ijcard.2012.11.067

Chicago

Zhang, Yuan, Maros Elsik, Amanda J Edgley, Alison J Cox, Andrew R Kompa, Bing Wang, Christina Yan Ru Tan, et al. 2013. “A New Anti-Fibrotic Drug Attenuates Cardiac Remodeling and Systolic Dysfunction Following Experimental Myocardial Infarction.” International Journal of Cardiology 168 (2): 1174–85. doi:10.1016/j.ijcard.2012.11.067.